Akebia Therapeutics Holds Stockholder Meeting

TL;DR

Akebia held a shareholder vote on June 6th. Details to follow.

AI Summary

Akebia Therapeutics, Inc. filed an 8-K on June 10, 2024, reporting that on June 6, 2024, the company held a special meeting of its stockholders. The primary purpose of this meeting was to vote on matters presented to security holders, as detailed in the filing.

Why It Matters

This filing indicates a formal process of shareholder engagement and voting on corporate matters, which is a standard but important governance event for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a routine corporate governance disclosure regarding a shareholder meeting, with no immediate financial or operational risks indicated.

Key Players & Entities

• Akebia Therapeutics, Inc. (company) — Registrant
• June 6, 2024 (date) — Date of earliest event reported
• June 10, 2024 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• 245 First Street Cambridge, Massachusetts 02142 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.00001 — ich registered Common Stock, par value $0.00001 per share AKBA The Nasdaq Capital Marke

Filing Documents

• akba-20241006cfo.htm (8-K) — 40KB
• 0001517022-24-000057.txt ( ) — 42KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. Akebia Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders on June 6, 2024 (the "Annual Meeting") to consider and vote upon the matters listed below. The following is a summary of the matters voted on at the Annual Meeting and the results of the votes on such matters. 1. The proposal to elect three Class I directors, Ronald E. Frieson, Steven C. Gilman, Ph.D. and Cynthia Smith, to serve until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal was approved as follows Director Votes For Votes Withheld Broker Non-Votes Ronald E. Frieson 60,670,984 37,772,419 38,195,337 Steven C. Gilman, Ph.D. 67,980,247 30,463,156 38,195,337 Cynthia Smith 67,799,627 30,643,776 38,195,337 2. The proposal to approve an amendment to the Company's 2023 Stock Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 9,800,000 shares was not approved as follows Votes For 45,155,875 Votes Against 52,820,792 Abstentions 466,736 Broker Non-Votes 38,195,337 3. The proposal to approve, on an advisory basis, the compensation of the Company's named executive officers was approved as follows Votes For 48,857,959 Votes Against 47,361,877 Abstentions 2,223,567 Broker Non-Votes 38,195,337 4. The proposal to ratify the selection of Ernst Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was approved as follows Votes For 120,235,723 Votes Against 13,578,974 Abstentions 2,824,043 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AKEBIA THERAPEUTICS, INC. Date June 10, 2024 By s John P. Butler Name

View Full Filing

View this 8-K filing on SEC EDGAR